Provectus Biopharmaceuticals (PVCT)
(Delayed Data from OTC)
$0.11 USD
+0.01 (12.54%)
Updated Sep 5, 2024 03:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Provectus Biopharmaceuticals, Inc. [PVCT]
Reports for Purchase
Showing records 1 - 20 ( 56 total )
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage due to the departure of covering analyst.
Provider: Roth Capital Partners, Inc.
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are suspending coverage in order to focus on other areas of interest to our institutional clients.
Provider: STONEGATE CAPITAL MARKETS
Analyst: RODRIGUEZ M
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Re-cap of Positive PV-10 in Melanoma Phase II Results and KOL Comments
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are placing Provectus Pharmaceuticals under review due to the departure from the firm of covering analyst
Provider: RODMAN & RENSHAW, CO.
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Research Update: PVCT: Q112 Results and Top Line Phase II Data for PH 10
Provider: STONEGATE CAPITAL MARKETS
Analyst: ENGEL L
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Increased Awareness of Intralesional Therapy Bodes Well for PV-10 Outlook
Provider: Roth Capital Partners, Inc.
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Provectus Biopharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Robust results from PV-10 in melanoma trial support promising outlook
Provider: Roth Capital Partners, Inc.